Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Anumigilimab by CSL for Hidradenitis Suppurativa: Likelihood of Approval
Anumigilimab is under clinical development by CSL and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Data Insights
Anumigilimab by CSL for Acute Respiratory Distress Syndrome: Likelihood of Approval
Anumigilimab is under clinical development by CSL and currently in Phase I for Acute Respiratory Distress Syndrome. According to GlobalData,...